Safety and Pharmacokinetics of Piperacillin-tazobactam Extended Infusion in Infants and Children (PIP-TAZO)
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Severe infection is one of the main causes of disease in hospitalized children and can be
deadly. With the lack of novel antibiotics approved in children and the emergence of drug
resistant bacteria, there is a critical need to optimize dosing of existing antibiotics.
Piperacillin-tazobactam is an antibiotic frequently used for treatment of severe infection in
children in Canadian hospitals. To optimize this antibiotic's efficacy despite the rise of
antibiotic resistance, alternative dosing strategy is commonly used in adults, which consists
of prolonging the time during which the drug is infused (4 hours instead of 30 min). Children
clear piperacillin-tazobactam from their bodies at a slower rate than adults, consequently
extended-infusion strategy cannot be directly extrapolated from adult to children. We believe
that younger children need piperacillin-tazobactam infusions that are shorter compared to
adults to achieve appropriate concentrations.
Phase:
Phase 1
Details
Lead Sponsor:
St. Justine's Hospital
Treatments:
Penicillanic Acid Piperacillin Piperacillin, Tazobactam Drug Combination Tazobactam